The National Institute for Health and Clinical Excellence (NICE): How Does It Work and What Are the Implications for the U.S.? (Executive Summary)

The National Institute for Health and Clinical Excellence (NICE): How Does It Work and What Are the Implications for the U.S.? (Executive Summary)

A study commissioned by the National Pharmaceutical Council examines key learnings from the U.K.'s National Institute for Health and Clinical Excellence (NICE), the organization that provides guidance to the National Health Service on the clinical and economic effects of various medical treatments. The study's authors, Dr. Michael Drummond and co-authors at the London School of Economics, provide an overview of NICE and present their conclusions about what the U.K.'s experiences mean for establishing a more formalized system for collecting comparative effectiveness information in the United States.

The full report is also available on NPC’s website.

Blog Post

CER Tweets of the Week: PCORI Looks Forward to 2015 CER Survey, Awards $64M for Five CER Studies (February 23-27)

This week, comparative effectiveness research (CER) stakeholders tweeted about registration opening for the National Pharmaceutical Council’s (@...
Newsletter Volume

E.V.I.dently February 2015

NPC MessageBiopharmaceutical Innovation and the Changing Health Care SystemDuring the last decade, we have seen significant progress in...
Blog Post

CER Tweets of the Week: #HealthDataChat, UNC Calls for Abstracts for Its CER Symposium (February 16-20)

This week, comparative effectiveness research (CER) stakeholders engaged in a #healthdatachat with AcademyHealth (@edm_ah), @Health_Affairs and the...
Blog Post

Fifth Annual Survey on CER & Health Care Decision-Making: What Can We Expect This Year?

Every year since 2011, we’ve been keeping our finger on the pulse of health care stakeholders to gauge their opinions about comparative effectiveness...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
YouTube Videos

Incorporating Patient Views Into Health Technology Assessments

David Grainger, senior director, global public policy, Eli Lilly and Company, explains that many health technology assessments are incorporating...
YouTube Videos

Health Technology Assessments and Specialty Medications

David Grainger, senior director, global public policy, Eli Lilly and Company, says that there are often challenges in conducting health technology...
YouTube Videos

Differences in Global Health Technology Assessment

David Grainger, senior director, global public policy, Eli Lilly and Company, describes how health technology assessment (HTA) informs policy and...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

CER Tweets of the Week: PCORI Looks Forward to 2015 CER Survey, Awards $64M for Five CER Studies (February 23-27)

This week, comparative effectiveness research (CER) stakeholders tweeted about registration opening for the National Pharmaceutical Council’s (@...
Blog Post

CER Tweets of the Week: #HealthDataChat, UNC Calls for Abstracts for Its CER Symposium (February 16-20)

This week, comparative effectiveness research (CER) stakeholders engaged in a #healthdatachat with AcademyHealth (@edm_ah), @Health_Affairs and the...
Blog Post

Fifth Annual Survey on CER & Health Care Decision-Making: What Can We Expect This Year?

Every year since 2011, we’ve been keeping our finger on the pulse of health care stakeholders to gauge their opinions about comparative effectiveness...
Blog Post

CER Tweets of the Week: WSUTL CER Symposium Call for Posters, Health Affairs Big Data Chat, #PMINetwork Meeting (February 9-13)

This week, comparative effectiveness research (CER) stakeholders tweeted about the Washington University in St. Louis Institute for Public Health’s...

Research

  •  
  • 1 of 32
  • >

Commentary & Testimony